{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:38:22Z","timestamp":1781872702172,"version":"3.54.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Immune checkpoint inhibitor therapy has demonstrated an overall survival benefit in patients with advanced melanoma. Though the significance of programmed death-ligand 1 (PD-L1) expression on melanoma cells as a predictive biomarker of response remains inconclusive, some reports indicate that a PD-L1 expression of &lt;1% of tumor cells may be associated with better outcomes with dual immunotherapy. Adequate patient selection for combination therapy is critical given the higher frequency of adverse effects compared with monotherapy. Immunohistochemical (IHC) PD-L1 interpretation in tumor cells is challenging when inflammatory cells are present and cutoffs are low. We studied 36 metastatic melanoma biopsies from Immune checkpoint inhibitor\u2013naive patients, previously stained and scored for PD-L1 IHC using the tumor proportion score (TPS). Cases were classified into 3 groups: &lt;1%, 1% to 5%, and &gt;5%. After de-coverslipping, SRY-related HMG-box-10 (SOX10) IHC was performed on PD-L1 IHC slides with a red chromogen, and subsequently scanned and scored by \u22652 dermatopathologists. This assessment determined that 25% of cases (9\/36) had a TPS \u2265 1%, in contrast to the single IHC assay (63.8%). The majority of the 1-5% group (11\/13, 84.6%) underwent a change of category to &lt;1% TPS. In the &gt;5% group, 60% of cases (6\/10) were downgraded to &lt;1% and 1% to 5% (4 and 2 cases, respectively). Our study suggests that PD-L1 IHC evaluation could benefit from dual PD-L1\/SOX10 IHC. Dual IHC is expected to decrease the interference caused by PD-L1 expression on inflammatory cells, and digital imaging proves useful for the preservation and analysis of stains. Refining PD-L1 evaluation in metastatic melanoma may improve clinical decisions between single and combination immunotherapy, with potentially profound consequences in response and quality of life.<\/jats:p>","DOI":"10.1097\/pas.0000000000002322","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:00:10Z","timestamp":1728295210000},"page":"1551-1556","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Dual PD-L1\/SOX10 Immunohistochemistry Combined With Digital Imaging Enhances Stratification Accuracy of Patients With Metastatic Melanoma"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-5393","authenticated-orcid":false,"given":"Juan","family":"Pineda-Reyes","sequence":"first","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Krishna","family":"Arudra","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu P.","family":"Aung","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadharsini","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Dermatology"},{"name":"Department of Translational Molecular Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tetzlaff","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Translational Molecular Pathology"},{"name":"Dermatopathology and Oral Pathology Unit, The University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lien","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jen","family":"Hwu","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres-Cabala","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Dermatology"},{"name":"Department of Translational Molecular Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/genes14061252","article-title":"Immunohistochemical expression of programmed cell death ligand 1 (PD-L1) in human cutaneous malignant melanoma: a narrative review with historical perspectives","volume":"14","author":"Cazzato","year":"2023","journal-title":"Genes"},{"key":"R4-20250608","first-page":"15","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2022","journal-title":"Biomol Biomed"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"e006947","DOI":"10.1136\/jitc-2023-006947","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0","volume":"11","author":"Pavlick","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J Pers Med"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/diagnostics13061041","article-title":"PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors\u2019 response and survival in advanced melanoma patients in Brazil","volume":"13","author":"Sorroche","year":"2023","journal-title":"Diagnostics"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"104774","DOI":"10.1016\/j.ebiom.2023.104774","article-title":"Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multi-center cohort study ADOREG\/TRIM","volume":"96","author":"Placke","year":"2023","journal-title":"eBioMedicine"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/PAI.0000000000000605","article-title":"Development of a diagnostic programmed cell death 1-ligand 1 immunohistochemistry assay for nivolumab therapy in melanoma","volume":"26","author":"Phillips","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2217\/imt-2016-0025","article-title":"PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1\/PD-L1 agents: a meta-analysis","volume":"8","author":"Rahman","year":"2016","journal-title":"Immunother"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2023.05.002","article-title":"Ancillary testing for melanoma: current trends and practical considerations","volume":"140","author":"Hosler","year":"2023","journal-title":"Human Pathology"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.amjms.2020.03.020","article-title":"Prognostic and clinicopathological value of PD-L1 in melanoma: a meta-analysis","volume":"359","author":"Xu","year":"2023","journal-title":"Am J Med Sci"},{"key":"R14-20250608","first-page":"1995","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Once"},{"issue":"IU","key":"R15-20250608","first-page":"1","article-title":"A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"R16-20250608","first-page":"210","article-title":"Biomarkers for Response to Anti-PD-1\/Anti-PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis.","volume":"37","author":"Mariam","year":"2023","journal-title":"Oncology (Williston Park)"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"104193","DOI":"10.1016\/j.critrevonc.2023.104193","article-title":"Preoperative Therapy in melanoma: evolving perspectives in clinical TrialsShort title: melanoma preoperative therapies","volume":"193","author":"Kakish","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Eng J Med"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Eng J Med"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/his.13528","article-title":"Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma","volume":"73","author":"Koelzer","year":"2018","journal-title":"Histopathology"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41416-018-0168-9","article-title":"Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy","volume":"119","author":"Dupuis","year":"2018","journal-title":"Br J Cancer"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1038\/s41598-018-28944-3","article-title":"Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma","volume":"8","author":"Halse","year":"2018","journal-title":"Sci Rep"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.arcmed.2020.09.008","article-title":"Pathology-based biomarkers useful for clinical decisions in melanoma","volume":"51","author":"Torres-Cabala","year":"2020","journal-title":"Arch Med Res"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"810858","DOI":"10.3389\/fmolb.2022.810858","article-title":"Validation of an accurate automated multiplex immunofluorescence method for immuno-profiling melanoma","volume":"9","author":"Yaseen","year":"2022","journal-title":"Front Mol Biosci"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/cancers15102768","article-title":"Reproducibility in PD-L1 immunohistochemistry quantification through the tumor proportion score and the combined positive score: could dual immunostaining help pathologists?","volume":"15","author":"Mercier","year":"2023","journal-title":"Cancers"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T20:01:11Z","timestamp":1749412871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002322","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}